跳至主要内容
临床试验/NL-OMON36805
NL-OMON36805招募中不适用

Cervical Arthroplasty Study: Cadisc*-C Total Disc Replacement - CASCADE

Clinical and Regulatory Affairs0 个研究点目标入组 15 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • 1. Skeletally mature patients (aged 18 years 65 years),
  • 2. Not pregnant or lactating at the time of surgery,
  • 3. Has cervical disc syndrome as defined as radiculopathy with or without accompanying cervical pain with symptomatic nerve root compression documented by patient history, clinical examination and confirmed by MRI or CT/myelogram, showing cervical disc herniation or nerve root entrapment
  • 4. One level cervical disc syndrome where the implantation may or may not be adjacent to a pre-existent fusion
  • 5. Proposed surgical level at C3- C7 inclusive,
  • 6. Unresponsive to conservative, i.e. non-surgical management, such as pharmaceutical, physiotherapy or surgical micro-discectomy/decompression for six weeks or presence of progressive symptoms or signs of cord compression,
  • 7. No previous surgical procedures at the involved level or any planned surgical procedure at the involved or adjacent level other than outlined in inclusion criterion 4,
  • 8. Arm Pain score of >= 20 based on Visual Analogue Scale, may be with Preop Neck Disability index score >= 30
  • 9. Capable of and willing to comply to the study protocol in the opinion of the Investigator, including a is willingness to return to the hospital for all the required post-operative follow-up visits,
  • 10. Capable of and willing to provide voluntary, written informed consent to participate in this investigation and from whom written consent must be obtained prior to enrolment.
  • 11. Mild signs of myelopathy without change to the spinal cord as seen on T2-MRI

排除标准

  • a. Arm pain confirmed as non discogenic in origin
  • b. Undergone previous cervical spinal surgery at the index level that could affect the trial outcome (e.g., disc replacement or previous fusion),
  • c. Radiographic evidence of facet degeneration or severe facet disease,
  • d. Active infection or metastatic, autoimmune or terminal disease
  • e. Osteoporosis, osteopenia or other metabolic bone disease or endocrine disorder known to affect osteogenesis,
  • f. Significant spinal deformity such as osteophytes, sclerotic facets,
  • g. Pre-existing neurological abnormalities or other deficits, e.g. Parkinson*s disease, diabetic neuropathy, MS, cerebro-vascular accident, peripheral neuropathy,
  • h. Significant loss of disc height >50%
  • i. Clinically compromised vertebral bodies at the affected level due to current or past trauma
  • j. Subject is skeletally immature as determined by the investigator
  • k. Instability of the cervical spine as defined radiographically (Panjabi & White [1990]), if suspected:
  • a. Flexion extension saggital plane translation >3.5mm or 20% and saggital plane rotation > 20°, OR
  • b. Resting X-rays: saggital plane displacement > 3.5mm or 20% and relative saggital plane angulation >11º
  • l. Myelopathy with change to the spinal cord as seen on T2-MRI
  • m. Morbid Obesity BMI>40
  • n. Unwillingness or inability to give consent or adhere to the follow-up programme
  • o. Drug or alcohol dependency
  • p. Currently involved in injury litigation
  • q. Known allergy to any of the implant materials
  • r. Subject has participated in another clinical investigation or study with an investigational medical device within the last 60 days
  • s. Concomitant medications that are known significantly to interfere with bone/soft tissue healing, e.g. steroids.

研究者

发起方
Clinical and Regulatory Affairs

相似试验